Cardiovascular Diseases

Dose‐Response of Omega‐3 Fatty Acids for Lowering BP

A dose‐response meta‐analysis suggested that the optimal combined intake of omega‐3 fatty acids for blood pressure (BP) lowering is likely between 2 g/d and 3 g/d. Doses above 3 g/d may be associated with additional benefits in lowering BP among high risk groups for cardiovascular diseases. The analysis included 71 randomized controlled trials published before May 7, 2021, involving 4973 individuals with a combined docosahexaenoic acid+eicosapentaenoic acid dose of 2.8 g/d (interquartile range, 1.3 g/d to 3.6 g/d). A random‐effects 1‐stage cubic spline regression model was used to predict the average dose‐response association between daily omega‐3 fatty acid intake and changes in BP. A nonlinear J‐shaped dose‐response association was found overall or in most subgroups. The optimal intake for both systolic BP and diastolic BP reductions (mm Hg) were obtained by moderate doses between 2 g/d (systolic BP, −2.61; diastolic BP, −1.64) and 3 g/d (systolic BP, −2.61; diastolic BP, −1.80). Subgroup studies revealed stronger and approximately linear dose‐response relations among hypertensive, hyperlipidemic, and older populations. The findings provide robust evidence in the beneficial effect of omega‐3 fatty acids for reducing cardiovascular risks despite a mixed evidence base and the potential risks of increased atrial fibrillation and bleeding. In addition to the effect on BP, omega‐3 fatty acids have other effects on hyperlipidemia, inflammation, and thrombosis. Foods high in omega‐3 fatty acids include seafoods, nuts, seeds and plant oils. Source: https://www.ahajournals.org/

hyangiu

Recent Posts

Lifestyle Intervention May Slow Early Cerebral Small-Vessel Injury

A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…

15 hours ago

Shared and Region-Specific Dementia Risk Factors

Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…

21 hours ago

Comparative Benefits and Risks of Anti-Obesity Drugs

A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…

4 days ago

Early Mild Hypertrophic Cardiomyopathy May Still Carry Significant Cardiovascular Risk

Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…

6 days ago

High-Intensity Interval Exercise Reduces Energy Intake in Adults With Overweight or Obesity

A Danish randomized crossover trial found that a single session of high-intensity interval exercise (HIIE)…

7 days ago

Proton Pump Inhibitor and Antibiotic Use May Reduce the Benefit of Immunotherapy in NSCLC

Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated…

1 week ago

This website uses cookies.